1. (a) The chief executive officer of Connecticut Innovations, Incorporated, shall (1) develop a donated funds program to encourage the development of funds other than state appropriations for regenerative medicine research in the state, (2) examine and identify specific ways to improve and promote for-profit and not-for-profit regenerative medicine research and research in related areas in the state, including, but not limited to, identifying both public and private funding sources for such research, maintaining existing regenerative medicine-related businesses, recruiting new regenerative medicine-related businesses to the state and recruiting scientists and researchers in such field to the state, (3) administer a regenerative medicine research assistance program that shall provide financial assistance to eligible institutions for the advancement of regenerative medicine research in the state pursuant to section 32-41kk, (4) monitor the regenerative medicine research conducted by eligible institutions that receive such financial assistance, and (5) prepare a comprehensive strategic plan for the Regenerative Medicine Research Fund, established pursuant to section 32-41kk, and financial assistance awarded from said fund that shall include, but need not be limited to, identification of specific methods or strategies to (A) achieve the scientific and economic development objective of said fund, (B) build innovation capacity, and (C) sustain investments of moneys received by said fund.

2. (b) Connecticut Innovations, Incorporated, shall serve as administrator of the Regenerative Medicine Research Fund and shall:

   1. (1) Develop the application for the financial assistance authorized under subsection (b) of section 32-41kk; (2) review such applications; (3) review recommendations of peer reviewers pursuant to section 32-41mm; (4) prepare and execute any assistance agreements or other agreements in connection with the awarding of such financial assistance; (5) develop performance metrics and systems to collect data from recipients of such financial assistance; and (6) collect information from such recipients concerning each recipient's employment statistics, business accomplishments and performance outcomes, peer review articles and papers published, partnerships and collaborations with other entities, licenses, patents and invention disclosures, scientific progress as it relates to the commercialization of intellectual property funded by such financial assistance, efforts to commercialize such intellectual property, and other funds received for research.

(P.A. 05-149, S. 3; P.A. 06-33, S. 1; P.A. 10-117, S. 43; P.A. 11-242, S. 39; P.A. 14-98, S. 34; P.A. 15-55, S. 1; 15-222, S. 3; P.A. 23-204, S. 240.)

History: P.A. 05-149 effective June 15, 2005; P.A. 06-33 amended Subsec. (a) by designating existing provisions as Subdiv. (1) and adding Subdiv. (2) requiring the appointment of eight additional members by July 1, 2006, and amended Subsec. (d) by describing what shall not constitute a conflict of interest and authorizing members to participate in the review or consideration of grant-in-aid applications, effective April 24, 2006; P.A. 10-117 deleted former Subsec. (g) re annual reports from committee to Governor and General Assembly; P.A. 11-242 amended Subsec. (a)(1) by permitting commissioner's designee to be a member of committee and amended Subsec. (b) by permitting commissioner's designee to serve as committee chairperson; P.A. 14-98 amended Subsec. (a) by replacing “Stem Cell Research Advisory Committee” with “Regenerative Medicine Research Advisory Committee”, adding chief executive officer of Connecticut Innovations, Incorporated, as member, adjusting qualifications for members appointed by Governor and minority leader of the House of Representatives, and removing restriction on members' concurrent service on peer review committee in Subdiv. (1), and adjusting qualifications for members appointed by Governor, president pro tempore of the Senate, speaker of the House of Representatives and minority leader of the House of Representatives, and removing restriction on members' concurrent service on peer review committee in Subdiv. (2), deleted former Subsec. (b) re Commissioner of Public Health as chairperson, added new Subsec. (b) re chief executive officer of Connecticut Innovations, Incorporated, as chairperson, amended Subsec. (e) by adding Subdiv. (5) re strategic plan, amended Subsec. (f) by replacing former provisions with provisions re duties of Connecticut Innovations, Incorporated, and replaced references to embryonic and human adult stem cell with references to regenerative medicine and made technical and conforming changes throughout; Sec. 19a-32f transferred to Sec. 32-41ll in 2015; P.A. 15-55 amended Subsec. (f)(2) by replacing “Regenerative Medicine Research Advisory Committee” with “Regenerative Medicine Peer Review Committee”, effective June 19, 2015; P.A. 15-222 replaced references to grants-in-aid with references to financial assistance and made conforming changes in Subsecs. (d) to (f), and amended Subsec. (f)(3) by replacing reference to Regenerative Medicine Research Advisory Committee with reference to peer reviewers, effective July 1, 2015; P.A. 23-204 deleted former Subsecs. (a) to (d) re establishment and membership of Regenerative Medicine Research Advisory Committee, redesignated existing Subsec. (e) as Subsec. (a) and amended same to replace reference to advisory committee with chief executive officer of Connecticut Innovations, Incorporated and made a conforming change and redesignated existing Subsec. (f) as Subsec. (b) and amended same to delete reference to advisory committee and delete former Subdiv. (7) re administrative duties, effective July 1, 2023.